17
Participants
Start Date
April 30, 2011
Primary Completion Date
October 31, 2011
Study Completion Date
April 30, 2013
CO-1.01 Formulation A (Aqueous suspension containing 15 mg/mL of drug solubilized in purified phospholipids)
1250 mg/m2 intravenous infusion on Day 1 for Treatment Sequence 1 and Day 8 for Treatment Sequence 2.
CO-1.01 Formulation B (Aqueous suspension containing 30 mg/mL of drug solubilized in purified phospholipids)
1250 mg/m2 intravenous infusion on Day 1 for Treatment Sequence 2 and Day 8 for Treatment Sequence 1.
The Netherlands Cancer Institute, Amsterdam
Maastricht University Medical Center, Maastricht
University Medical Center Utrecht, Utrecht
Lead Sponsor
Clovis Oncology, Inc.
INDUSTRY